Feline immunodeficiency virus vaccine: Implications for diagnostic testing and disease management

Novel fused tetrathiocines as antivirals that target the nucleocapsid zinc finger containing protein of the feline immunodeficiency virus (FIV) as a model of HIV infection

A novel series of fused tetrathiocines were prepared for evaluation of activity against the nucleocapsid protein of the feline immunodeficiency virus (FIV) in an in vitro cell culture approach. The results demonstrated that the compounds display potent nanomolar activity and low toxicity against this key model of HIV infection.

Evaluation of the antiviral efficacy of bis[1,2]dithiolo[1,4]thiazines and bis[1,2]dithiolopyrrole derivatives against the nucelocapsid protein of the Feline Immunodeficiency Virus (FIV) as a model for HIV infection

A diverse library of bis[1,2]dithiolo[1,4]thiazines and bis[1,2]dithiolopyrrole derivatives were prepared for evaluation of activity against the nucleocapsid protein of the Feline Immunodeficiency Virus (FIV) as a model for HIV, using an in vitro cell culture approach, yielding nanomolar active compounds with low toxicity.

Feline immunodeficiency. ABCD guidelines on prevention and management

Overview

Feline immunodeficiency virus (FIV) is a retrovirus closely related to human immunodeficiency virus. Most felids are susceptible to FIV, but humans are not. Feline immunodeficiency virus is endemic in domestic cat populations worldwide. The virus loses infectivity quickly outside the host and is susceptible to all disinfectants.

Infection

Feline immunodeficiency virus is transmitted via bites. The risk of transmission is low in households with socially well-adapted cats. Transmission from mother to kittens may occur, especially if the queen is undergoing an acute infection. Cats with FIV are persistently infected in spite of their ability to mount antibody and cell-mediated immune responses.

Disease signs

Infected cats generally remain free of clinical signs for several years, and some cats never develop disease, depending on the infecting isolate. Most clinical signs are the consequence of immunodeficiency and secondary infection. Typical manifestations are chronic gingivostomatitis, chronic rhinitis, lymphadenopathy, weight loss and immune-mediated glomerulonephritis.

Diagnosis

Positive in-practice ELISA results obtained in a low-prevalence or low-risk population should always be confirmed by a laboratory. Western blot is the ‘gold standard’ laboratory test for FIV serology. PCR-based assays vary in performance.

Disease management

Cats should never be euthanased solely on the basis of an FIV-positive test result. Cats infected with FIV may live as long as uninfected cats, with appropriate management. Asymptomatic FIV-infected cats should be neutered to avoid fighting and virus transmission. Infected cats should receive regular veterinary health checks. They can be housed in the same ward as other patients, but should be kept in individual cages.

Vaccination recommendations

At present, there is no FIV vaccine commercially available in Europe. Potential benefits and risks of vaccinating FIV-infected cats should be assessed on an individual cat basis. Needles and surgical instruments used on FIV-positive cats may transmit the virus to other cats, so strict hygiene is essential.

New challenges for the diagnosis of feline immunodeficiency virus infection

Vaccination of cats against feline immunodeficiency virus (FIV) with a whole-virus vaccine results in rapid and persistent production of antibodies that are indistinguishable from those used for diagnosis of FIV infection. There are no diagnostic tests available for veterinary practitioners at the present time to resolve the diagnostic dilemma posed by use of whole-virus vaccines for protection of cats against FIV. There is a great need for development of commercially available rapid diagnostic tests that conform to differentiation of infected from vaccinated animals standards.

Feline immunodeficiency virus vaccine: a rational paradigm for clinical decision-making

A veterinarian must take into consideration his/her responsibility to prevent disease when assessing the needs of a client's cat that is risk for FIV infection based on its established lifestyle. Cats infected with FIV have debilitated immune functions and exhibit a high level of chronic morbidity impacting on the animal's welfare and the owner's economic abilities to maintain the pet. Attempts to reduce the prevalence of FIV solely by advising clients to maintain their cats indoors has resulted in poor compliance and not impacted on a change in infection rates with outdoor cats. Therapeutics have not impacted on outcomes in infected animals. There has a need for a vaccine for high-risk cats. Options for vaccines that do not confound the current FIV antibody test have not been efficacious against a broad spectrum of isolates. Fel-O-Vax FIV, a conventional non-marker whole virus, has shown good efficacy against heterologous challenges. The intervention should be discussed with cat owners since the vaccine has a reasonable expectation of preventing FIV infection in cats at risk without undue safety issues. Veterinarians who do not initiate this dialogue with owners who have outdoor cats in an environment where 2.5% of cats in the USA are infected may be remiss in their professional responsibilities.